BACKGROUND: Chemotherapy for early breast cancer is associated with a small risk of developing myelodysplastic syndrome (MDS) and/or acute myeloid leukemia (AML). The aim of this study was to determine the risk of developing AML or MDS after modern adjuvant chemotherapy in older breast cancer patients and to further define the risk of individual chemotherapy regimens. ; HR for A1T, 1.68; 95% CI, 1.22-2.30) or MDS (HR for A, 2.18; 95% CI, 1.70-2.80; HR for A1T, 1.62; 95% CI, 1.29-2.03) than patients who did not receive chemotherapy. Patients using docetaxel and cyclophosphamide (TC) were not at increased risk for AML or MDS. CONCLUSIONS: Adjuvant chemotherapy is associated with a small but significant increase in the risk of AML and MDS, especially with regimens that include A. Longer follow-up is needed to confirm that risk is not increased with the recently adopted TC regimen. Cancer 2018;124:899-906.
INTRODUCTION
Adjuvant chemotherapy for breast cancer has significantly improved the outcomes of patients of all ages. 1 Chemotherapy is not without risk because both short-and long-term complications can occur, and this likely contributes to decreased utilization in older patients. The risk of developing secondary malignancies has been well described with breast cancer regimens. Therapy-related acute myeloid leukemia (t-AML) that is associated with alkylating agents usually occurs 5 to 7 years after exposure to chemotherapy and is preceded by myelodysplastic syndrome (MDS). t-AML that is associated with topoisomerase II agents usually occurs with a shorter latency (less than 5 years) and is associated with an 11q23 translocation. t-AML confers a poor prognosis and is particularly worse for patients with unfavorable cytogenetics. 2 The rates of t-AML and/or MDS after breast cancer have been described in multiple clinical trials and in large database analyses; they range from 0.6% to 1.8%. [3] [4] [5] However, these evaluations do not take into account the current practice patterns of adjuvant chemotherapy use in the United States. Since 2005, the use of docetaxel and cyclophosphamide (TC), a taxane-based regimen without an anthracycline (A), has significantly increased in frequency. 6 Consequently, in this analysis, we investigated the rates of acute myeloid leukemia (AML) and MDS in an older breast cancer cohort that received modern adjuvant chemotherapy regimens, including TC.
MATERIALS AND METHODS
The Surveillance, Epidemiology, and End Results (SEER)/Texas Cancer Registry (TCR)-Medicare linked databases were retrospectively reviewed and analyzed. The SEER program collects data from tumor registries covering 28% of the US population and is supported by the US National Cancer Institute (NCI). The Medicare program is administered by the Centers for Medicare and Medicaid Services and covers 97% of the US population aged 65 years or older. 7 Under an agreement between the NCI and the Centers for Medicare and Medicaid Services, SEER participants are matched with their Medicare record. Of the SEER participants who are diagnosed with cancer when they are 65 years old or older, 94% are matched with their Medicare enrollment records.
The TCR is a statewide population-based registry and is a component of the Texas Department of State Health Services. The TCR is not part of SEER but collects data according to the standardized registry rules and is gold-certified by the North American Association of Central Cancer Registries. Using the same methodology used for the SEER-Medicare linkage, the NCI linked the TCR databases with Texas Medicare data by means of a probabilistic linkage model.
We identified patients who were 65 years old or older and were diagnosed with invasive breast cancer between 2003 and 2009. SEER-Medicare patients were followed until December 31, 2014, and TCR-Medicare patients were followed until December 31, 2012. Only patients with localized or regional disease were included. In addition, patients were required to have Medicare Part A and Part B coverage during the full year after diagnosis and to not be enrolled in a health maintenance organization because Medicare claims were not complete for these members. Patients who received chemotherapy other than an anthracycline, a taxane, or cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) were excluded.
Patients who developed AML or MDS were identified by disease-specific International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes extracted from inpatient, outpatient, and provider claims. In an effort to ensure the accuracy of the diagnosis for inpatient claims, we required the ICD-9-CM code to be one of the first 2 diagnosis codes. For outpatient claims, patients were required to have at least 2 outpatient/provider claims, with the ICD-9-CM code used at least 30 days apart.
Chemotherapy patients were defined by Medicare claims within 1 year of diagnosis and were placed into 1 of the following 5 cohorts: A-based (patients with claims with at least 1 of the Healthcare Common Procedure Coding System [HCPCS] codes for doxorubicin, liposomal doxorubicin, or epirubicin and no taxanes given), taxane-based (patients with claims that had at least 1 of the HCPCS codes for docetaxel, nab-paclitaxel, or paclitaxel and no A given), anthracycline and taxane (A1T), or CMF (patients with claims with HCPCS codes for all 3 drugs). The taxane group was further classified as TC (docetaxel and cyclophosphamide) and other taxanes (most of which were trastuzumab-based, US Food and Drug Administration-approved regimens or a taxane without cyclophosphamide). The ICD-9-CM and Current Procedural Terminology/HCPCS codes used in the study are listed in Supporting Table 1 (see online supporting information). The frequencies of the regimens in each chemotherapy group are listed in Supporting Table 2 (see online supporting information).
Descriptive statistics were used. Patient characteristics and treatments were compared according to the chemotherapy categories with the chi-square test. The cumulative incidence function of AML/MDS subject to the competing risk of death was estimated for each chemotherapy group, and the cumulative incidence function between groups was compared with Gray's test. 8, 9 Incidence rates were calculated as the number of AML/MDS events per 1000 person-years at risk for each chemotherapy, and 95% confidence intervals (CIs) for incidence rates were computed with a Poisson distribution. The 3-, 5-, and 8-year cumulative incidences with 95% CIs were estimated with the univariate Kaplan-Meier method.
Multivariate Cox regression models were applied to estimate hazard ratios (HRs) and 95% CIs for developing AML and MDS. The following variables were included in the final model: age, year of diagnosis, race, geographic region, marital status, urban/rural status, socioeconomic variables (education and poverty levels), tumor grade, surgery type, radiation therapy exposure, other malignancies, and Charlson comorbidity index. 10, 11 Other malignancies were identified from the breast cancer diagnosis to the end of follow-up or the development of AML/MDS. This variable was treated as a time-dependent covariate in the multivariate Cox regression models. P values less than .05 were considered statistically significant; all tests were 2-sided. All the statistical analyses were performed with SAS 9.4 (SAS Institute, Inc, Cary, North Carolina). Table 1 .
Among the 92,110 patients, the median follow-up was 85 months (91 months for SEER-Medicare participants and 64 months for TCR-Medicare participants). Patients who were treated with A-based chemotherapy had the longest median follow-up at 104 months, and all other chemotherapy groups had a similar median followup (84 months for the no-chemotherapy group, 88 months for the A1T group, 79 months for the TC group, 73 months for the other taxane group, and 94 months for the CMF group). The median number of cycles was 4 for the A-based group, 7 for the A1T group, 4 for the TC group, 5 for the other taxane group, and 6 for the CMF group. A sensitivity analysis was performed to determine the dose-response effects of chemotherapy on AML/ MDS, and no significant difference was detected (Supporting Table 3 [see online supporting information]). In addition, patients who received a combination of chemotherapy and radiation therapy did not show a significantly increased risk of AML/MDS (Supporting Table 4 [see online supporting information]).
Among the 92,110 breast cancer patients, the overall incidence rates for AML and MDS were 0.65 (95% CI, 0.59-0.71) and 1.56 (95% CI, 1.47-1.66) per 1000 person-years, respectively. Among the 71,886 patients with no chemotherapy, the incidence rates for AML and MDS were 0.59 (95% CI, 0.53-0.66) and 1.42 (95% CI, 1.32-1.53) per 1000 person-years, respectively. Among the 20,224 patients who received chemotherapy, the incidence rates for AML and MDS were 0.85 (95% CI, 0.71-1.01) and 2.05 (95% CI, 1.83-2.30) per 1000 personyears, respectively. The median times from the breast cancer diagnosis to AML and MDS were 39 and 26 months, respectively.
Patients treated with A-based therapy (whose incidence rates for AML and MDS were 1.05 and 2.52 per 1000 person-years, respectively) and patients treated with A1T therapy (whose incidence rates for AML and MDS were 1.03 and 1.88 per 1000 person-years, respectively) developed AML and MDS more frequently than patients treated with TC (whose incidence rates for AML and MDS were 0.32 and 1.22 per 1000 person-years, respectively). Patients treated with CMF (whose incidence rates for AML and MDS were 0.74 and 2.39 per 1000 personyears, respectively) and patients treated with other taxanes (whose incidence rates for AML and MDS were 0.51 and 2.42 per 1000 person-years, respectively) had lower AML incidence rates but similar MDS incidence rates in comparison with patients treated with A-based and A1T therapies, as shown in Figure 2 .
The cumulative incidence of developing AML and MDS is illustrated in Figure 3 . Patients who received Abased and A1T-containing regimens were more likely to develop AML than patients who did not receive chemotherapy. No difference in the AML incidence was found between patients who received taxane-based chemotherapy or CMF and the no-chemotherapy cohort. Patients who received chemotherapy were more likely to develop MDS than patients who did not, except for the TC cohort. The specific 3-, 5-, and 8-year cumulative incidences of the outcomes under study are presented in Table 2 . Similarly, patients who received A-based and A1T regimens showed higher cumulative incidences of AML and MDS at all years in comparison with patients without chemotherapy. Patients receiving the TC regimen were similarly as likely to develop AML and MDS as patients without chemotherapy (among patients at risk, 0.13%, 0.17%, and 0.22% in the TC group and 0.21%, 0.32%, and 0.45% in the no-chemotherapy group developed AML at 3, 5, and 8 years, respectively; 0.47%, 0.67%, and 0.91% in the TC group and 0.62%, 0.88%, and 1.11% in the no-chemotherapy group developed MDS at 3, 5, and 8 years, respectively).
In a Cox regression model, patients who received an A-based regimen (HR, 1.70; 95% CI, 1.16-2.50) or A1T (HR, 1.68; 95% CI, 1.22-2.30) were more likely to develop AML than patients not treated with chemotherapy. There was no significantly increased risk when patients who received TC (HR, 0.62; 95% CI, 0.27-1.41), other taxanes (HR, 0.88; 95% CI, 0.43-1.79), or CMF (HR, 1.11, 95% CI, 0.62-1.99) were compared Table 3 .
DISCUSSION
In our analysis, we identified the risk of AML and MDS for older patients with local-or regional-stage breast cancer. The 8-year cumulative incidence for patients who did not receive chemotherapy was 0.45% for AML and 1.11% for MDS. For patients who received A-based and A1T regimens, the cumulative incidence was significantly higher for both AML (0.90% and 0.84%, respectively) and MDS (2.24% and 1.55%, respectively). These results can be added to previous estimates of secondary myeloid malignancies after breast cancer.
In an analysis of 3 large Cancer and Leukemia Group B adjuvant trials, in which 6174 women with node-positive breast cancer received doxorubicin and cyclophosphamidebased therapy, the 5-year cumulative incidence for AML and MDS combined was 0.6%. Among patients who were 65 years old or older, 1.8% developed AML/MDS. Although this estimate suggests that older patients are at much higher risk, this cumulative incidence should be viewed with caution because only 7% of the participants were 65 years old or older. 4 Despite a concerted effort from cooperative groups to increase the recruitment of older patients, 12 including designing trials specifically for this patient population, 13 older patient enrollment in clinical trials remains low. In a recent review of all Alliance breast cancer clinical trials from 1985 to 2012, 17% of the study participants were 65 years old or older.
14 With limited numbers of patients in clinical trials, retrospective analyses can help us to define the benefits and risks involved in treatments.
In a study using the SEER-Medicare linked database of breast cancer patients diagnosed from 1992 to 2002, a 10-year cumulative incidence of 1.2% for AML in breast cancer patients was observed among patients who did not receive chemotherapy, and a 10-year cumulative incidence of 1.8% was observed for patients treated with adjuvant chemotherapy. 5 Differing from our analysis, this study did not evaluate MDS because Medicare did not have a unique ICD-9-CM code for MDS at that time. In addition, the chemotherapy regimens included are likely no longer representative of current practices because the group of patients receiving non-A, nontaxane chemotherapy was the largest cohort of patients (45.8%).
Another relevant study evaluating data from the National Comprehensive Cancer Network revealed that 0.24% of patients with early-stage breast cancer at 5 years and 0.48% of these patients at 10 years developed marrow neoplasms, including malignancies of myeloid and lymphoid origins. 3 The authors estimated the incidence rate of marrow neoplasms among patients receiving chemotherapy to be 0.46 per 1000 person-years.
Unique to our analysis is the fact that we evaluated the risk associated with all modern regimens, including TC. This is relevant because this adjuvant chemotherapy regimen has become widely used. In a separate population-based study, TC was identified as the most frequently used regimen among breast cancer patients younger than 65 years. 15 Our results indicate that TC was not associated with an increased risk of AML or MDS in comparison with no chemotherapy. However, it is known that the exposure to the alkylating agent cyclophosphamide is associated with a risk of developing secondary myeloid malignancies that occur 7 years after exposure. Because of the relatively recent adaptation of TC, longer follow-up and additional patients are needed to truly define the risk for AML and/or MDS associated with this regimen. This limitation can possibly be seen in our evaluation of MDS because the HR for TC is in the direction of risk but does not reach statistical significance. We cannot exclude the idea that with larger numbers of patients and longer follow-up, an increased risk might be identified in a future analysis. Despite this limitation, in our cohort, patients treated with TC had a median follow-up of 79 months, and this provides an informative estimate because this regimen was the most commonly used regimen in 2008 and 2009.
Our study is limited by its retrospective nature and characteristics inherent in claim-based research. Though unlikely, it is possible that patients may have been lost or misclassified; this could explain the lower rates of cases in comparison with other studies focusing on elderly patients.
The question of the efficacy of TC versus A1T-based therapy had not been fully addressed until recently. The results of a joint analysis of the Anthracycline in Early Breast Cancer (ABC) trials revealed a significantly different 4-year invasive disease-free survival rate of 88.2% with TC, whereas for an A1T-based regimen, it was 90.7% (P 5 .04). 16 In this joint analysis, at a median follow-up of 3.3 years, the cumulative incidence of acute leukemia was 0.24% (5 of 2062) in the A1T cohort. No cases of leukemia were identified in the TC cohort. This finding was consistent with our results showing that the TC regimen was associated with a lower risk of AML than other regimens, although the follow-up time in this study was not long enough for an affirmative conclusion to be drawn.
Overall, our data provide valid estimations of the risk of a devastating complication secondary to chemotherapy usage. The greatest strength of our analysis is that it is the largest study to date evaluating incidence rates of AML and MDS among breast cancer patients who received no chemotherapy and breast cancer patients treated with contemporary adjuvant chemotherapy regimens. The risk of AML/MDS remains small but significant. It is important to carefully select patients who will truly benefit from chemotherapy and select the appropriate regimen according to each patient's risk. Gene signature assays can be used in appropriate scenarios to identify appropriate candidates for chemotherapy.
Using the results from our study, practicing oncologists can more accurately estimate the risk involved with developing secondary myeloid diseases.
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